SAN FRANCISCO--(BUSINESS WIRE)--Encellin, a biotechnology company developing a cell encapsulation platform with an initial focus on Type 1 Diabetes (T1D), announced the closing of a $9.9M financing ...
LAS VEGAS, NEVADA, Sept. 30, 2026 (GLOBE NEWSWIRE) -- (OTCQB: AVAI) (“Avaí” or the “Company”), an emerging biotech developing transformative cell-based therapies for diabetes, age-related disorders, ...
Avaí Bio, Inc. (OTCQB: AVAI) (“Avaí” or the “Company”) and its joint venture partner Austrianova, today announced the first ...
A cell is fundamentally a container—a vessel that encapsulates life at the most basic level. Many biologists believe encapsulation of chemicals may have been necessary for evolution to gain traction.
LAS VEGAS, Dec. 16, 2025 /PRNewswire/ -- Avant Technologies, Inc. (OTCQB: AVAI) ("Avant" or the "Company"), an emerging biotechnology company focused on developing cell-based therapies for diabetes ...
LAS VEGAS, NEVADA, Sept. 24, 2026 (GLOBE NEWSWIRE)-- Avaí Bio, Inc. (OTCQB: AVAI) ("Avaí” or the "Company”), together with joint venture partner Austrianova, today announced that Prof. Walter H.
In 2020, there were 2.3 million women diagnosed with breast cancer. Deaths related to cancer occur due to metastasis. In most types of solid tumors, spreading happens through collective migration, ...
Avai Bio and Austrianova established Insulinova as an equally owned joint venture to explore encapsulated cell-based therapies for diabetes. Under the collaboration with OSR, the partners will ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results